Chandraditya Chakraborty, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 6 | 2017 | 2039 | 0.640 |
Why?
|
| Multiple Myeloma | 6 | 2025 | 5194 | 0.530 |
Why?
|
| Cervix Uteri | 1 | 2017 | 575 | 0.440 |
Why?
|
| beta Catenin | 1 | 2017 | 1048 | 0.400 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2021 | 8621 | 0.360 |
Why?
|
| Neoplasm Proteins | 2 | 2020 | 3601 | 0.320 |
Why?
|
| Human papillomavirus 16 | 4 | 2015 | 268 | 0.310 |
Why?
|
| Uterine Cervical Dysplasia | 3 | 2015 | 391 | 0.260 |
Why?
|
| Receptors, Cell Surface | 1 | 2014 | 2815 | 0.240 |
Why?
|
| DNA Methylation | 3 | 2015 | 4427 | 0.230 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2024 | 5329 | 0.210 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2025 | 661 | 0.180 |
Why?
|
| 14-3-3 Proteins | 1 | 2020 | 221 | 0.160 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2019 | 196 | 0.160 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2025 | 3607 | 0.160 |
Why?
|
| Ecosystem | 1 | 2022 | 490 | 0.150 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2022 | 630 | 0.150 |
Why?
|
| Papillomavirus Infections | 3 | 2015 | 1639 | 0.140 |
Why?
|
| Evolution, Molecular | 2 | 2023 | 1892 | 0.130 |
Why?
|
| Genomics | 3 | 2023 | 5923 | 0.120 |
Why?
|
| Prognosis | 2 | 2021 | 29948 | 0.120 |
Why?
|
| Oligopeptides | 1 | 2020 | 1195 | 0.120 |
Why?
|
| Ubiquitin | 1 | 2019 | 841 | 0.120 |
Why?
|
| Adenocarcinoma | 2 | 2023 | 6359 | 0.120 |
Why?
|
| Sulfonamides | 1 | 2024 | 1982 | 0.120 |
Why?
|
| Genomic Instability | 3 | 2024 | 716 | 0.110 |
Why?
|
| Oncogene Proteins, Viral | 2 | 2015 | 342 | 0.110 |
Why?
|
| Cell Transformation, Viral | 1 | 2015 | 527 | 0.110 |
Why?
|
| Cell Cycle Proteins | 1 | 2025 | 3439 | 0.110 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 2015 | 434 | 0.110 |
Why?
|
| Epithelium | 1 | 2017 | 1606 | 0.100 |
Why?
|
| Bone Marrow | 1 | 2022 | 2926 | 0.100 |
Why?
|
| Cell Proliferation | 2 | 2025 | 10445 | 0.090 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2011 | 109 | 0.090 |
Why?
|
| HeLa Cells | 1 | 2017 | 3073 | 0.090 |
Why?
|
| Apoptosis | 2 | 2025 | 9513 | 0.090 |
Why?
|
| Antineoplastic Agents | 2 | 2024 | 13643 | 0.090 |
Why?
|
| Esophageal Neoplasms | 1 | 2021 | 1660 | 0.090 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 3944 | 0.080 |
Why?
|
| Interleukin-1beta | 1 | 2015 | 1026 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 3 | 2015 | 5789 | 0.080 |
Why?
|
| Immunotherapy | 1 | 2024 | 4747 | 0.080 |
Why?
|
| DNA, Viral | 1 | 2015 | 2201 | 0.070 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 1751 | 0.070 |
Why?
|
| Cell Line, Tumor | 5 | 2025 | 17088 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2025 | 12150 | 0.060 |
Why?
|
| E2F1 Transcription Factor | 1 | 2025 | 182 | 0.060 |
Why?
|
| Repressor Proteins | 2 | 2015 | 2978 | 0.060 |
Why?
|
| Epigenesis, Genetic | 2 | 2015 | 3824 | 0.060 |
Why?
|
| Mutation | 2 | 2021 | 30213 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 11218 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2021 | 6104 | 0.050 |
Why?
|
| Melphalan | 1 | 2024 | 425 | 0.050 |
Why?
|
| Chromosomal Instability | 1 | 2023 | 176 | 0.050 |
Why?
|
| Deoxyribonucleases | 1 | 2023 | 209 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 4049 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2025 | 1756 | 0.040 |
Why?
|
| Humans | 14 | 2025 | 766766 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2025 | 996 | 0.040 |
Why?
|
| India | 2 | 2015 | 2335 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 1405 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2023 | 2510 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2021 | 2628 | 0.030 |
Why?
|
| Female | 8 | 2021 | 396520 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2023 | 2926 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2016 | 369 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 2016 | 437 | 0.030 |
Why?
|
| Human papillomavirus 18 | 1 | 2015 | 125 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2023 | 2839 | 0.030 |
Why?
|
| Virus Integration | 1 | 2015 | 307 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2021 | 6222 | 0.020 |
Why?
|
| Mice | 3 | 2025 | 81889 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2024 | 3043 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2015 | 588 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2025 | 5795 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2025 | 5690 | 0.020 |
Why?
|
| Open Reading Frames | 1 | 2011 | 818 | 0.020 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2015 | 1363 | 0.020 |
Why?
|
| Aged | 3 | 2015 | 171343 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 2045 | 0.020 |
Why?
|
| Survival Rate | 1 | 2021 | 12825 | 0.020 |
Why?
|
| Animals | 3 | 2025 | 168930 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2016 | 16044 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2015 | 1466 | 0.020 |
Why?
|
| Middle Aged | 3 | 2015 | 223257 | 0.020 |
Why?
|
| Disease Progression | 2 | 2015 | 13640 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2025 | 18330 | 0.020 |
Why?
|
| Cell Line | 1 | 2015 | 15563 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 20144 | 0.010 |
Why?
|
| Prevalence | 1 | 2015 | 15835 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2015 | 9611 | 0.010 |
Why?
|
| Inflammation | 1 | 2015 | 10860 | 0.010 |
Why?
|
| Male | 2 | 2023 | 364142 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 18075 | 0.010 |
Why?
|
| Adult | 2 | 2015 | 223307 | 0.010 |
Why?
|